MedTrace Logo

A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions

NCT00865033 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-03-29

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.

Conditions

Interventions

DRUG

Metformin HCL Tablets, 1000 mg Sandoz

DRUG

Glucophage 1000 mg

Sponsors & Collaborators

Principal Investigators

  • Soran Hong, M.D. · Novum Pharmaceutical Research Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2005-11-30
Completion
2005-11-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00865033 on ClinicalTrials.gov